Skip to main content

Table 1 Results of the clinical assessment and telomere length (TL) comparison between control subjects (CG), lifetime depressed with irrelevant symptoms (IS) and with relevant symptoms of depression (RS)

From: Telomere shortening in leukocyte subpopulations in depression

 

Group

N

Mean

SD

Overall test

CG vs. IS

IS vs. RS

Age (years)

CG

50

51.1

8

χ2 2 = 2.10,

  

IS

24

53.1

7.2

p = .35

RS

20

53.8

7.6

Education (years)

CG

50

15.1

2.4

χ2 2 = 3.05,

  

IS

24

14.1

2.1

p = .22

RS

20

14.2

2.9

Age at first depressive episode (years)

CG

50

-

    

IS

24

37.2

12.6

  

t 36.8 = 1.33,

RS

20

31.5

15.4

p = .19

Total depressive episodes

CG

50

-

-

   

IS

24

2.4

1.0

  

W = 176.5,

RS

20

3.2

2.1

p = .27

BDI

CG

50

3.2

2.8

χ2 2 = 53.7,

W = 253,

W = 5.5,

IS

24

7.5

4.8

p < .0001

p = .0003

p < .0001

RS

20

21.7

7.4

  

SSRI/ SNRI intake

CG

0 of 50

     

IS

10 of 24

    

χ 2 2 = .33,

RS

9 of 20

p = .56

L-Thyroxine intake

CG

3 of 50

  

χ2 2 = 1.26,

  

IS

1 of 24

p = .53

RS

0 of 20

CD4+ TL (%)

CG

48

67.77

16.05

See text for detailed models and results

IS

24

55.06

15.73

RS

20

53.09

17.88

CD8+ TL (%)

CG

45

68.7

13.69

See text for detailed models and results

IS

24

51.1

11.98

RS

17

48.76

13.07

CD20+ TL (%)

CG

44

68.83

16.83

See text for detailed models and results

IS

23

47.44

9.44

RS

16

50

13.69

Hypertension

CG

1 of 50

     

IS

1 of 24

 

RS

2 of 20

     
  1. TL of the reference sample (30 years old healthy male subject) was set to 100%. TL of CD4+, CD8+, and CD20+ cells given in % related to the reference. BDI, Beck Depression Inventory; SSRI, selective serotonine reuptake inhibitors; SNRI, serotonine and norepinephrine reuptake inhibitors; L-Thyroxine, treatment for hypothyreosis.